Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of JNJ-87189401 combined with JNJ-78278343 in advanced prostate cancer
NL-OMON60245Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of JNJ-87189401 and pasritamig in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Planned start Apr 2024; status: withdrawn.
02
Drugs
JNJ-87189401pasritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON60245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60245.